Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Existing plans for drug use during flu pandemic can reduce wastewater treatment efficiency

Existing plans for antiviral and antibiotic use during a severe influenza pandemic could reduce wastewater treatment efficiency prior to discharge into receiving rivers, resulting in water quality deterioration at drinking water abstraction points.

2 Mar 2011

Depression negatively impacts outcomes of care in patients with CRS: New research

Depression is a common problem in patients with chronic rhinosinusitis and negatively impacts patients' symptom burden, ability to function, and quality of life, according to new research published in the March 2011 issue of Otolaryngology - Head and Neck Surgery.

1 Mar 2011

Renishaw launches first RUO multiplex assay system

Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of surface enhanced Raman scattering and surface enhanced resonance Raman scattering, for research and molecular diagnostics applications, today announced the launch of its first research use only multiplex assay system which allows precious research samples to be 'screened' for 10 or more 'targets', from a single sample.

1 Mar 2011

Positive results from Trius torezolid Phase 1 lung study

Trius Therapeutics, Inc. today announced results from its Phase 1 clinical trial to evaluate the ability of torezolid to penetrate into the lung for potential use to treat lung infections. In this study a 200 mg dose of torezolid phosphate was administered orally once-daily for three days to healthy adult volunteers. The trial achieved its primary goal of establishing the steady-state plasma pharmacokinetics and distribution of active drug into epithelial lining fluid (ELF).

28 Feb 2011

Arsanis closes Series A financing for $10 million

Arsanis, Inc, a recently founded biotechnology company dedicated to the development of anti-infective monoclonal antibody therapeutics, today announced the closing of a Series A financing with a total funding amount of $10 million. Proceeds from the initial financing will be used to advance several programs in the anti-microbial infectious disease area.

28 Feb 2011

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

Salix Pharmaceuticals, Ltd. today announced that based on a telephone conversation with the U.S. Food and Drug Administration held last evening, the Company anticipates receiving a Complete Response Letter on or before the March 7, 2011 PDUFA goal date for the supplemental New Drug Application for XIFAXAN 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome and IBS-related bloating.

25 Feb 2011

Researchers identify probiotic bacterial strain that may treat ulcers caused by H. pylori

Researchers from Spain have identified a strain of probiotic bacteria that may be useful in treating ulcers caused by Helicobacter pylori. They report their findings in the February 2011 issue of the journal Applied and Environmental Microbiology.

25 Feb 2011

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, today announced the successful completion of a Phase 1 exposure-escalation clinical study with its synthetic defensin-mimetic antibiotic, PMX-30063.

24 Feb 2011

Signaling mechanism in bacterial ribosome linked to antibiotic resistance

Researchers at the University of Illinois at Chicago have discovered a signaling mechanism in the bacterial ribosome that detects proteins that activate genes for antibiotic resistance.

23 Feb 2011

Nanoparticle therapy may improve survival after life-threatening blood loss

In an advance that could improve battlefield and trauma care, scientists at Albert Einstein College of Medicine of Yeshiva University have used tiny particles called nanoparticles to improve survival after life-threatening blood loss.

23 Feb 2011

New DNA technology to study cystic fibrosis 'superbug' during infection

The bacterium, called Pseudomonas aeruginosa, is the most common cause of persistent and fatal lung infections in cystic fibrosis patients. Scientists at Liverpool identified a particularly virulent strain of the bacteria that is transmissible between patients. The Liverpool Epidemic Strain (LES), referred to as a cystic fibrosis 'superbug', can cause aggressive infection and results in progressive lung decline.

23 Feb 2011

'Day on Deadly Killers'

Experts from Europe, the US and Asia will present their research results and discuss how new therapeutical approaches against infectious diseases may look like.

22 Feb 2011

Researcher finds antibiotic in Eastern Red Cedar tree effective against MRSA

Most people would never suspect that a "trash tree," one with little economic value and often removed by farmers due to its ability to destroy farmland, could be the key to fighting a deadly bacterium. Now, a University of Missouri researcher has found an antibiotic in the Eastern Red Cedar tree that is effective against methicillin-resistant Staphylococcus aureus, a "superbug" that is resistant to most medications.

22 Feb 2011

Scientists show bacteria in polluted rivers become resistant to range of antibiotics

Many of the substances in our most common medicines are manufactured in India. Some of these factories release huge quantities of drugs to the environment. Swedish scientists now show that bacteria in polluted rivers become resistant to a range of antibiotics. International experts fear that this may contribute to the development of untreatable infectious diseases world-wide.

21 Feb 2011

Proper wound care may treat skin infections effectively than antibiotics in children with MRSA

When it comes to curing skin infected with the antibiotic-resistant bacterium MRSA, timely and proper wound cleaning and draining may be more important than the choice of antibiotic, according to a new Johns Hopkins Children's Center study. The work is published in the March issue of Pediatrics.

21 Feb 2011

Fast Company ranks NovaBay 7th in biotech industry in 2011 annual list of world's most innovative companies

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has been ranked seventh in the biotech industry in Fast Company's annual list of the world's most innovative companies in 2011.

19 Feb 2011

Impax' NDA for generic version of Adoxa receives final FDA approval

Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration has granted final approval of the Company's Abbreviated New Drug Application for its generic version of Adoxa.

18 Feb 2011

Experts say signs and treatment of bacterial infection often misunderstood

According to the Canadian Foundation for Infectious Diseases, antibiotics are the second most frequently prescribed class of drugs - second only to pain relievers. Yet most people don't know the difference between a true bacterial infection, like chronic bronchitis that can be treated with antibiotics — and viruses like the common cold, which cannot.

17 Feb 2011

Silver nanoparticle coated 'killer paper' for food packaging

Scientists are reporting development and successful lab tests of "killer paper," a material intended for use as a new food packaging material that helps preserve foods by fighting the bacteria that cause spoilage. The paper, described in ACS's journal, Langmuir, contains a coating of silver nanoparticles, which are powerful anti-bacterial agents.

17 Feb 2011

Over 20% of young children with respiratory viral infections will develop middle ear infections

More than 20 percent of young children with colds or other respiratory viral infections will develop middle ear infections of varying severity—including some mild infections that don't require antibiotics, according to a study in the February issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

16 Feb 2011

Antibiotic News and Research

Further Reading

Existing plans for drug use during flu pandemic can reduce wastewater treatment efficiency

Depression negatively impacts outcomes of care in patients with CRS: New research

Renishaw launches first RUO multiplex assay system

Positive results from Trius torezolid Phase 1 lung study

Arsanis closes Series A financing for $10 million

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

Researchers identify probiotic bacterial strain that may treat ulcers caused by H. pylori

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

Signaling mechanism in bacterial ribosome linked to antibiotic resistance

Nanoparticle therapy may improve survival after life-threatening blood loss

New DNA technology to study cystic fibrosis 'superbug' during infection

'Day on Deadly Killers'

Researcher finds antibiotic in Eastern Red Cedar tree effective against MRSA

Scientists show bacteria in polluted rivers become resistant to range of antibiotics

Proper wound care may treat skin infections effectively than antibiotics in children with MRSA

Fast Company ranks NovaBay 7th in biotech industry in 2011 annual list of world's most innovative companies

Impax' NDA for generic version of Adoxa receives final FDA approval

Experts say signs and treatment of bacterial infection often misunderstood

Silver nanoparticle coated 'killer paper' for food packaging

Over 20% of young children with respiratory viral infections will develop middle ear infections

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News